{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:33:47Z","timestamp":1790505227214,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,10,2]],"date-time":"2007-10-02T00:00:00Z","timestamp":1191283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2007,10,17]]},"DOI":"10.1007\/s10557-007-6053-z","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T14:09:59Z","timestamp":1191247799000},"page":"357-365","source":"Crossref","is-referenced-by-count":17,"title":["Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model"],"prefix":"10.1007","volume":"21","author":[{"given":"Stavros I.","family":"Chrysostomakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis K.","family":"Karalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel N.","family":"Simantirakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios V.","family":"Koutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hercules E.","family":"Mavrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory I.","family":"Chlouverakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos E.","family":"Vardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,10,2]]},"reference":[{"key":"6053_CR1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","volume":"306","author":"WB Kannel","year":"1982","unstructured":"Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018\u201322.","journal-title":"N Engl J Med"},{"key":"6053_CR2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946\u201352.","journal-title":"Circulation"},{"key":"6053_CR3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/01.CIR.0000062689.04037.3F","volume":"107","author":"J Ausma","year":"2003","unstructured":"Ausma J, van der Velden HM, Lenders MH, van Ankeren EP, Jongsma HJ, Ramaekers FC, et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003;107:2051\u20138.","journal-title":"Circulation"},{"key":"6053_CR4","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","volume":"92","author":"MC Wijffels","year":"1995","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954\u201368.","journal-title":"Circulation"},{"key":"6053_CR5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0735-1097(03)00464-9","volume":"41","author":"K Kumagai","year":"2003","unstructured":"Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197\u20132204.","journal-title":"J Am Coll Cardiol"},{"key":"6053_CR6","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1161\/01.CIR.101.22.2612","volume":"101","author":"H Nakashima","year":"2000","unstructured":"Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612\u20137.","journal-title":"Circulation"},{"key":"6053_CR7","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1161\/01.CIR.96.9.3157","volume":"96","author":"J Ausma","year":"1997","unstructured":"Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157\u201363.","journal-title":"Circulation"},{"key":"6053_CR8","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/01.CIR.101.23.2678","volume":"101","author":"A Goette","year":"2000","unstructured":"Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678\u201381.","journal-title":"Circulation"},{"key":"6053_CR9","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0735-1097(00)00611-2","volume":"35","author":"A Goette","year":"2000","unstructured":"Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"6053_CR10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","volume":"27","author":"JR Ehrlich","year":"2006","unstructured":"Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006;27:512\u20138.","journal-title":"Eur Heart J"},{"key":"6053_CR11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cardiores.2004.03.026","volume":"63","author":"N Hanna","year":"2004","unstructured":"Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236\u201344.","journal-title":"Cardiovasc Res"},{"key":"6053_CR12","doi-asserted-by":"crossref","first-page":"H2487","DOI":"10.1152\/ajpheart.00462.2004","volume":"287","author":"K Funabiki","year":"2004","unstructured":"Funabiki K, Onishi K, Dohi K, Koji T, Imanaka-Yoshida K, Ito M, et al. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am J Physiol Heart Circ Physiol 2004;287:H2487\u201392.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"6053_CR13","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/01.CIR.0000016826.62813.F5","volume":"105","author":"K Shinagawa","year":"2002","unstructured":"Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672\u20138.","journal-title":"Circulation"},{"key":"6053_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.100.1.87","volume":"100","author":"D Li","year":"1999","unstructured":"Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87\u201395.","journal-title":"Circulation"},{"key":"6053_CR15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/415219a","volume":"415","author":"S Nattel","year":"2002","unstructured":"Nattel S. New ideas about atrial fibrillation 50\u00a0years on. Nature 2002;415:219\u201326.","journal-title":"Nature"},{"key":"6053_CR16","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/01.CIR.98.24.2765","volume":"98","author":"PE McEwan","year":"1998","unstructured":"McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998;98:2765\u201373.","journal-title":"Circulation"},{"key":"6053_CR17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.37.3.841","volume":"37","author":"DE Dostal","year":"2001","unstructured":"Dostal DE. Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 2001;37:841\u20134.","journal-title":"Hypertension"},{"key":"6053_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cardiores.2003.08.014","volume":"60","author":"S Cardin","year":"2003","unstructured":"Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60:315\u201325.","journal-title":"Cardiovasc Res"},{"key":"6053_CR19","first-page":"H308","volume":"261","author":"FG Spinale","year":"1991","unstructured":"Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991;261:H308\u201318.","journal-title":"Am J Physiol"},{"key":"6053_CR20","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1161\/01.CIR.92.8.2306","volume":"92","author":"J Kajstura","year":"1995","unstructured":"Kajstura J, Zhang X, Liu Y, Szoke E, Cheng W, Olivetti G, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995;92:2306\u201317.","journal-title":"Circulation"},{"key":"6053_CR21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cardiores.2003.12.013","volume":"61","author":"A Bauer","year":"2004","unstructured":"Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 2004;61:764\u201370.","journal-title":"Cardiovasc Res"},{"key":"6053_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0008-6363(99)00045-0","volume":"42","author":"BJ Brundel","year":"1999","unstructured":"Brundel BJ, van Gelder IC, Henning RH, Tuinenburg AE, Deelman LE, Tieleman RG, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res 1999;42:443\u201354.","journal-title":"Cardiovasc Res"},{"key":"6053_CR23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(99)00008-X","volume":"33","author":"LP Lai","year":"1999","unstructured":"Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, et al. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 1999;33:1231\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"6053_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.RES.85.5.428","volume":"85","author":"DR Wagoner Van","year":"1999","unstructured":"Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428\u201336.","journal-title":"Circ Res"},{"key":"6053_CR25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.RES.81.4.512","volume":"81","author":"L Yue","year":"1997","unstructured":"Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512\u201325.","journal-title":"Circ Res"},{"key":"6053_CR26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.RES.84.7.776","volume":"84","author":"L Yue","year":"1999","unstructured":"Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 1999;84:776\u201384.","journal-title":"Circ Res"},{"key":"6053_CR27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751\u20136.","journal-title":"Lancet"},{"key":"6053_CR28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611\u20136.","journal-title":"Lancet"},{"key":"6053_CR29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.hrthm.2004.08.008","volume":"1","author":"KT Murray","year":"2004","unstructured":"Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004;1:669\u201375.","journal-title":"Heart Rhythm"},{"key":"6053_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","volume":"44","author":"PL L\u2019Allier","year":"2004","unstructured":"L\u2019Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44:159\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"6053_CR31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","volume":"149","author":"AP Maggioni","year":"2005","unstructured":"Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548\u201357.","journal-title":"Am Heart J"},{"key":"6053_CR32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"AH Madrid","year":"2002","unstructured":"Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331\u20136.","journal-title":"Circulation"},{"key":"6053_CR33","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","volume":"24","author":"KC Ueng","year":"2003","unstructured":"Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090\u20138.","journal-title":"Eur Heart J"},{"key":"6053_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1071-9164(05)80004-1","volume":"1","author":"MP Berg Van Den","year":"1995","unstructured":"Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995;1:355\u201363.","journal-title":"J Card Fail"},{"key":"6053_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med 2002;113:359\u201364.","journal-title":"Am J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-007-6053-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-007-6053-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-007-6053-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:28:00Z","timestamp":1559237280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-007-6053-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10,17]]}},"alternative-id":["6053"],"URL":"https:\/\/doi.org\/10.1007\/s10557-007-6053-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,2]]}}}